# MediWound Ltd.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/MediWound Ltd.).

## Overview

MediWound Ltd. is an Israel-based biopharmaceutical company focused on enzymatic, non-surgical therapies for tissue repair and regeneration. Its portfolio centers on products for burn care, wound care, and related tissue restoration applications, with commercialization across selected global markets through direct sales and distributor channels.

## Products & services

• NexoBrid burn debridement therapy
• Enzymatic tissue repair and regeneration therapies
• Burn care commercialization and distribution
• Wound care and tissue restoration development
• Local regulatory and market access support via partners

- **Commercial burn therapy** (70%) — Approved and marketed treatment for eschar removal in severe thermal burns.
- **Wound care therapies** (20%) — Development-stage and emerging products aimed at wound management and repair.
- **Tissue repair platform** (10%) — Underlying enzymatic technology used to create new biotherapeutic candidates.

- NexoBrid burn debridement therapy
- Enzymatic tissue repair and regeneration therapies
- Burn care commercialization and distribution
- Wound care and tissue restoration development
- Local regulatory and market access support via partners

## Customers

MediWound sells primarily to burn centers, hospitals, and specialist clinicians that treat deep thermal burns and complex wounds. Its commercial model also relies on distributors and local partners in international markets that help secure market access and regulatory approvals. Research, procurement, and treatment decisions are driven by clinical outcomes, ease of use, and the ability to replace more invasive surgical procedures.

- **Burn centers** (primary) — Buy NexoBrid for treatment of severe burns requiring eschar removal.
- **Hospitals and specialist clinicians** (primary) — Use the product in acute care pathways for thermal burn management.
- **Distributors and local partners** (secondary) — Handle commercialization and market access in selected regions.
- **Healthcare systems** (secondary) — Adopt therapies that may reduce invasive surgery and support standardized care.

- Burn centers treating deep partial- and full-thickness burns
- Hospitals and specialist clinicians using eschar removal therapies
- International distributors responsible for local market access
- Healthcare systems seeking non-surgical wound solutions
- Clinical teams needing faster, standardized debridement options

## Geography

MediWound is headquartered and operates from Yavne, Israel, while its commercial footprint extends into the European Union, the United Kingdom, Israel, and other international markets. The company uses direct commercialization in some markets and distributor-led channels in Asia Pacific, EMEA, CEE, and LATAM, which broadens reach but increases dependence on local regulatory and partner execution. Its geography matters because market access, reimbursement, and approval timing vary significantly by country.

- **Israel** (20%) — Direct commercialization market and corporate base.
- **Europe** (40%) — Includes EU and United Kingdom direct sales and broader European distribution.
- **Asia Pacific** (20%) — Distributor-led commercial markets.
- **Latin America** (10%) — Distributor-led emerging market presence.
- **North America** (10%) — Includes regulatory presence and commercialization linked to U.S. approvals.

- Headquartered and operated from Yavne, Israel
- Direct sales to burn centers in the EU, UK, and Israel
- Distributor channels across Asia Pacific, EMEA, CEE, and LATAM
- Global commercialization depends on local marketing authorizations
- International market access varies by country and channel

## Strategy

MediWound’s strategy is built around its enzymatic technology platform and expanding it into multiple biotherapeutic indications beyond the initial burn-care franchise. The company is also focused on global commercialization of NexoBrid while advancing next-generation programs such as EscharEx, using partnerships and regulatory milestones to expand addressable markets. This approach seeks to combine a marketed product with a pipeline that can broaden the company’s long-term commercial base.

- **Grow the core NexoBrid franchise** (short-term) — A marketed product creates commercial traction, physician familiarity, and recurring market access infrastructure.
- **Advance EscharEx and other pipeline assets** (medium-term) — Pipeline expansion reduces dependence on a single product and broadens the clinical and commercial opportunity set.
- **Broaden international market access** (medium-term) — Local approvals and distributor relationships determine how quickly the company can reach new markets.

- Expand the enzymatic platform into additional therapeutic indications
- Grow NexoBrid commercialization across approved international markets
- Advance EscharEx toward regulatory approval and launch
- Use direct sales where possible and distributors where local access matters
- Leverage government and institutional support for development and scale-up

## Risks

MediWound depends on continued regulatory approvals, market access, and commercial adoption of a small number of products, which makes execution risk important. As a development-stage biopharmaceutical company with a marketed product and pipeline candidates, it also faces clinical, reimbursement, manufacturing, and partner-channel risks typical of specialty biotech businesses. Funding needs, government support assumptions, and foreign market dependence can materially affect operating flexibility.

- **Product concentration** [high] — A large share of commercial activity depends on NexoBrid, so any slower uptake or disruption can materially affect the business.
- **Regulatory and approval delays** [high] — The company needs approvals and authorizations across multiple jurisdictions before expanding sales.
- **Partner and distributor dependence** [medium] — Local distributors are responsible for market access in several territories, so execution quality affects adoption and timing.
- **Manufacturing and quality control** [high] — Biopharmaceutical products require consistent production, validation, and supply chain reliability.

- Reliance on NexoBrid concentrates revenue and commercial risk
- Pipeline timing risk if EscharEx or other candidates face delays
- Regulatory approvals differ by country and can slow expansion
- Distributor execution can affect international sales and market access
- Manufacturing and supply reliability are critical for biologic products

## Accounting

MediWound’s reported results are shaped by development-stage biotechnology accounting, where judgment is required around capitalization, stock compensation, and the pace of commercialization-related expense recognition. The company also relies on estimates for biological product inventories, intangible assets, and potential impairment, while share-based awards and grant-related support can affect comparability period to period. Because it operates internationally, foreign currency and interim reporting under IAS 34 can also influence reported volatility.

- **Revenue recognition** — Affects quarterly revenue timing and comparability.
- **Inventory valuation** — Can affect cost of sales and write-down risk.
- **Share-based compensation** — Affects operating expense and adjusted EBITDA reconciliation.
- **Intangible assets** — Can create non-cash charges if expected benefits weaken.

- Revenue timing may vary with product shipments and country-specific approvals
- Inventory valuation matters for biological products with limited shelf life
- Intangible assets and development spending may require impairment review
- Share-based compensation affects operating expense and adjusted metrics
- IAS 34 interim reporting can create quarter-to-quarter comparability swings

---

*Last updated: 2026-09-28T12:04:28.559394+00:00*